Peripheral T Cell Lymphomas Pipeline Analysis, 2023 Updates | Latest FDA, EMA, and PMDA Approvals | Celleron Therapeutics, Myeloid Therapeutics, Astex Pharmaceuticals, Citius Pharmaceuticals, Innate Pharma, Secura Bio, Genor Biopharma Co., Ltd., CerRx, In

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Peripheral T Cell Lymphomas pipeline constitutes 40+ key companies continuously working towards developing 40+ Peripheral T Cell Lymphomas treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Peripheral T Cell Lymphomas Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Peripheral T Cell Lymphomas Market.

The Peripheral T Cell Lymphomas Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Peripheral T Cell Lymphomas Pipeline Report: https://www.delveinsight.com/sample-request/peripheral-t-cell-lymphomas-ptcl-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Peripheral T Cell Lymphomas treatment therapies with a considerable amount of success over the years.
• Peripheral T Cell Lymphomas companies working in the treatment market are Applied Therapeutics, Autolus, Akeso Biopharma, Astex Pharmaceuticals, Secura Bio, Innate Pharma, Dizal Pharmaceutical, CSPC ZhongQi Pharmaceutical Technology, and others, are developing therapies for the Peripheral T Cell Lymphomas treatment
• Emerging Peripheral T Cell Lymphomas therapies in the different phases of clinical trials are- AT-104, Auto 5, AK 104, Tolinapant, Duvelisib, Lacutamab, AZD 4205, Mitoxantrone liposomal, and others are expected to have a significant impact on the Peripheral T Cell Lymphomas market in the coming years.
• In November 2022, Affimed N.V. and Artiva Biotherapeutics Inc. have announced a strategic collaboration aimed at jointly developing, producing, and marketing a combined therapy featuring Affimed's Innate Cell Engager (ICE) AFM13 and Artiva's AB-101, an off-the-shelf allogeneic NK cell product derived from cord blood and preserved through cryopreservation. Affimed has submitted a pre-IND meeting request to the FDA seeking guidance on the clinical trial design for the combined AFM13 and AB-101 therapy in relapsed/refractory Hodgkin lymphoma (HL). Additionally, the proposal includes an exploratory arm to assess the combination in relapsed/refractory CD30-positive peripheral T-cell lymphoma (PTCL) and outlines a potential pathway for regulatory approval. The FDA has responded to this request and indicated their intention to provide feedback by the first quarter of 2023.
• MT-101 is in development for addressing relapsed and refractory CD5-expressing T-cell lymphomas. Myeloid Therapeutics revealed in October 2022 that the US Food and Drug Administration (FDA) bestowed Fast Track Designation upon MT-101 for individuals dealing with refractory or relapsed CD5+ peripheral T cell lymphoma. Following the establishment of the recommended Phase II dose by Myeloid, plans include commencing a Phase II trial aimed at substantiating the drug's registration in this specific patient population.
• In September 2022, Yingli Pharma reported the initiation of a Phase II trial, marking the first dosing of a patient, focusing on a medication designed to address peripheral T cell lymphomas-a diverse and often aggressive group of neoplasms. The trial involves administering linperlisib, a potent inhibitor targeting the delta isoform of PI3 kinase, to patients dealing with relapsed or refractory peripheral T/NK cell lymphoma. This single-arm Phase II study aims to assess the safety, effectiveness, and pharmacokinetics of orally administered linperlisib. The trial is being conducted under a collaborative effort with The University of Texas MD Anderson Cancer Center.
• In September 2022, The European Commission has awarded orphan drug status to nanatinostat and valganciclovir (Nana-val) for potential use as a therapeutic approach in patients diagnosed with peripheral T-cell lymphoma (PTCL). Nanatinostat is specifically targeted at certain isoforms of class I HDACs, crucial in the epigenetic silencing of viral genes linked to Epstein-Barr virus (EBV)-associated malignancies. The compound is currently being studied in combination with valganciclovir.
• In June 2022, Kymera Therapeutics revealed that the FDA has granted orphan drug status to KT-333 intended for the treatment of Peripheral T-cell Lymphoma (PTCL). KT-333 represents a pioneering degrader targeting the transcriptional regulator STAT3, a crucial element in PTCL's disease modulation. Presently, there are no approved therapies addressing this pathway specifically for PTCL.


Peripheral T Cell Lymphomas Overview
A uncommon and diverse group of clinically aggressive diseases with a dismal prognosis, peripheral T-cell lymphoma (PTCL) accounts for 10%-15% of non-Hodgkin lymphomas (NHLs) in Western nations.

Get a Free Sample PDF Report to know more about Peripheral T Cell Lymphomas Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/peripheral-t-cell-lymphomas-ptcl-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Peripheral T Cell Lymphomas Drugs Under Different Phases of Clinical Development Include:
• AT-104: Applied Therapeutics
• Auto 5: Autolus
• AK 104: Akeso Biopharma
• Tolinapant: Astex Pharmaceuticals
• Duvelisib: Secura Bio
• Lacutamab: Innate Pharma
• AZD 4205: Dizal Pharmaceutical
• Mitoxantrone liposomal: CSPC ZhongQi Pharmaceutical Technology

Peripheral T Cell Lymphomas Route of Administration
Peripheral T Cell Lymphomas pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Subcutaneous
• Intravenous
• Oral
• Intramuscular
• Intra-tumoral
• Molecule Type

Peripheral T Cell Lymphomas Molecule Type
Peripheral T Cell Lymphomas Products have been categorized under various Molecule types, such as
• Monoclonal antibodies
• Immunoglobulins
• Small molecules
• Pyrimidines
• Proteins and Peptides
• Product Type

Peripheral T Cell Lymphomas Pipeline Therapeutics Assessment
• Peripheral T Cell Lymphomas Assessment by Product Type
• Peripheral T Cell Lymphomas By Stage and Product Type
• Peripheral T Cell Lymphomas Assessment by Route of Administration
• Peripheral T Cell Lymphomas By Stage and Route of Administration
• Peripheral T Cell Lymphomas Assessment by Molecule Type
• Peripheral T Cell Lymphomas by Stage and Molecule Type

DelveInsight's Peripheral T Cell Lymphomas Report covers around 40+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Peripheral T Cell Lymphomas product details are provided in the report. Download the Peripheral T Cell Lymphomas pipeline report to learn more about the emerging Peripheral T Cell Lymphomas therapies at:
https://www.delveinsight.com/sample-request/peripheral-t-cell-lymphomas-ptcl-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Peripheral T Cell Lymphomas Therapeutics Market include:
Key companies developing therapies for Peripheral T Cell Lymphomas are - Celleron Therapeutics, Myeloid Therapeutics, Astex Pharmaceuticals, Citius Pharmaceuticals, Innate Pharma, Secura Bio, Genor Biopharma Co., Ltd., CerRx, Inc., Dizal Pharmaceuticals, Kura Oncology, Inc., Viracta Therapeutics, Autolus Therapeutics, Affimed Therapeutics, C4 Therapeutics, Kymera Therapeutics, Daiichi Sankyo, SciTech Development LLC, Sorrento Therapeutics, Bristol-Myers Squibb, Shanghai Yingli Pharmaceutical, Ono Pharmaceutical, and others.

Peripheral T Cell Lymphomas Pipeline Analysis:
The Peripheral T Cell Lymphomas pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Peripheral T Cell Lymphomas with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Peripheral T Cell Lymphomas Treatment.
• Peripheral T Cell Lymphomas key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Peripheral T Cell Lymphomas Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Peripheral T Cell Lymphomas market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Peripheral T Cell Lymphomas drugs and therapies-
https://www.delveinsight.com/sample-request/peripheral-t-cell-lymphomas-ptcl-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Peripheral T Cell Lymphomas Pipeline Market Drivers
• Increase in incidences of PTCL, rising investment for the development of advanced technologies, surge in government initiatives to promote research and awareness about the disease are some of the important factors that are fueling the Peripheral T Cell Lymphomas Market.

Peripheral T Cell Lymphomas Pipeline Market Barriers
• However, high cost associated with the treatment, lack of skilled professionals for early diagnosis of the disease and other factors are creating obstacles in the Peripheral T Cell Lymphomas Market growth.

Scope of Peripheral T Cell Lymphomas Pipeline Drug Insight
• Coverage: Global
• Key Peripheral T Cell Lymphomas Companies: Applied Therapeutics, Autolus, Akeso Biopharma, Astex Pharmaceuticals, Secura Bio, Innate Pharma, Dizal Pharmaceutical, CSPC ZhongQi Pharmaceutical Technology, and others
• Key Peripheral T Cell Lymphomas Therapies: AT-104, Auto 5, AK 104, Tolinapant, Duvelisib, Lacutamab, AZD 4205, Mitoxantrone liposomal, and others
• Peripheral T Cell Lymphomas Therapeutic Assessment: Peripheral T Cell Lymphomas current marketed and Peripheral T Cell Lymphomas emerging therapies
• Peripheral T Cell Lymphomas Market Dynamics: Peripheral T Cell Lymphomas market drivers and Peripheral T Cell Lymphomas market barriers

Request for Sample PDF Report for Peripheral T Cell Lymphomas Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/peripheral-t-cell-lymphomas-ptcl-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Peripheral T Cell Lymphomas Report Introduction
2. Peripheral T Cell Lymphomas Executive Summary
3. Peripheral T Cell Lymphomas Overview
4. Peripheral T Cell Lymphomas- Analytical Perspective In-depth Commercial Assessment
5. Peripheral T Cell Lymphomas Pipeline Therapeutics
6. Peripheral T Cell Lymphomas Late Stage Products (Phase II/III)
7. Peripheral T Cell Lymphomas Mid Stage Products (Phase II)
8. Peripheral T Cell Lymphomas Early Stage Products (Phase I)
9. Peripheral T Cell Lymphomas Preclinical Stage Products
10. Peripheral T Cell Lymphomas Therapeutics Assessment
11. Peripheral T Cell Lymphomas Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Peripheral T Cell Lymphomas Key Companies
14. Peripheral T Cell Lymphomas Key Products
15. Peripheral T Cell Lymphomas Unmet Needs
16 . Peripheral T Cell Lymphomas Market Drivers and Barriers
17. Peripheral T Cell Lymphomas Future Perspectives and Conclusion
18. Peripheral T Cell Lymphomas Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Peripheral T Cell Lymphomas Market https://www.delveinsight.com/report-store/peripheral-t-cell-lymphoma-ptcl-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Peripheral T Cell Lymphomas Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Peripheral T Cell Lymphomas Epidemiology https://www.delveinsight.com/report-store/peripheral-t-cell-lymphoma-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Peripheral T Cell Lymphomas Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:
Ventricular Assist Devices Market https://www.delveinsight.com/report-store/ventricular-assist-devices-vad-market
Ventricular Assist Devices Market By Product Type (Left Ventricular Assist Devices, Right Ventricular Assist Devices, And Biventricular Assist Devices), By Application Type (Bridge-To-Transplant [Btt], Destination Therapy, And Others), By Design Type (Transcutaneous Ventricular Assist Devcies And Implantable Ventricular Assist Devices), By Type Of Flow (Pulsatile Flow And Continous Flow), By End User (Hospital And Clinics, Ambulatory Surgical Centers, And Others), by geography is expected to grow at a steady CAGR forecast till 2028 owing to the increasing prevalence of heart failure and cardiovascular diseases due to obesity, age, & unhealthy lifestyles and rising demand for organ transplants due to increasing prevalence of chronic ailments such as hypertension, diabetes, and others

B-cell Non-hodgkin Lymphoma Market https://www.delveinsight.com/report-store/b-cell-non-hodgkin-lymphoma-market
DelveInsight's "B-Cell Non-Hodgkin Lymphoma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the B-Cell Non-Hodgkin Lymphoma, historical and forecasted epidemiology as well as the B-Cell Non-Hodgkin Lymphoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Systemic Sclerosis Market
https://www.delveinsight.com/report-store/systemic-sclerosis-market
DelveInsight's "Systemic Sclerosis Market Insights, Epidemiology, and Market Forecast - 2032" comprehensively analyzes Systemic Sclerosis. The report includes a detailed examination of the historical and projected epidemiology data that includes diagnosed prevalent cases of Systemic Sclerosis segmented by gender-specific, age-specific, and type-specific cases.

Resorbable Vascular Scaffold Market
https://www.delveinsight.com/report-store/resorbable-vascular-scaffolds-market
"DelveInsight's 'Resorbable Vascular Scaffolds Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Resorbable Vascular Scaffolds and the historical and forecasted Resorbable Vascular Scaffolds market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Vascular Stents Market
https://www.delveinsight.com/report-store/vascular-stents-market
Vascular Stents Market By Product Type (Coronary Stents, Peripheral Stents [Carotid Stents, Iliac Stents, Femoral Stents, Femoral Stents, Other], Evar Stent Grafts [Abdominal Aortic Aneurysm Stents, Thoracic Aortic Aneurysm Stents]), By Type (Bare-Metal Stents, Drug-Eluting Stents), By Material (Metal And Polymer), By Mode Of Delivery (Balloon-Expandable Stents And Self Expandable Stents), By End-User (Hospitals And Ambulatory Surgical Centers), by geography, is expected to grow at a noteworthy CAGR forecast till 2028 owing to rising burden of vascular diseases across the globe and increasing preferences of minimally invasive surgeries among the patient population.

Bladder Scanners Market
https://www.delveinsight.com/report-store/bladder-scanners-market
"DelveInsight's 'Bladder Scanners Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Bladder Scanners and the historical and forecasted Bladder Scanners market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Vein Illumination Devices Market
https://www.delveinsight.com/report-store/vein-illumination-devices-market
"DelveInsight's 'Vein Illumination Devices Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Ventilator Market
https://www.delveinsight.com/report-store/ventilators-market
Ventilators Market By Mobility (Intensive Care Ventilators, Portable/Transportable Ventilators), By Type (Adult/Pediatric Ventilators, Neonatal/Infant Ventilators), By Interface (Invasive Ventilation, Non-Invasive Ventilation), By End-User (Hospitals, Home Care, Ambulatory Surgical Centers, Others), By Geography is expected to grow at a steady CAGR forecast till 2028 owing to launch of advanced devices and increasing prevalence of respiratory diseases such as COPD.

Vascular Graft Devices Market
https://www.delveinsight.com/report-store/vascular-grafts-market
Vascular Graft Devices Market By Product Type (Endovascular Grafts [Abdominal And Thoracic], Access Grafts, Peripheral Grafts, And Others), By Type (Knitted, Woven, And Others), By Material (Synthetic[ Polytetrafluoroethylene [PTFE], Polyester, Polyurethane], Biological, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), by geography is expected to register commendable revenue growth at a steady CAGR forecast till 2028 owing to increasing prevalence of cardiovascular diseases such as aortic aneurysms and peripheral artery disease and growing patient for kidney dialysis.

Patient Monitoring Devices Market
https://www.delveinsight.com/report-store/patient-monitoring-devices-market
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products.

Symptomatic Partial-thickness Rotator Cuff Tears Market
https://www.delveinsight.com/report-store/symptomatic-partial-thickness-rotator-cuff-tears-market
DelveInsight's "Symptomatic Partial-thickness Rotator Cuff Tears Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Symptomatic Partial-thickness Rotator Cuff Tears, historical and forecasted epidemiology as well as the Symptomatic Partial-thickness Rotator Cuff Tears market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Zika Virus Market
https://www.delveinsight.com/report-store/zika-virus-market
DelveInsight's "Zika Virus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+91-9650213330
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.